Dr. Brian M. Fernandez spoke about the design of AI models for ophthalmology at DOS Digital Day at ASCRS 2023, emphasizing the need for models to be safe, explainable, and interactive.
Read More
This article highlights OCT as an aid in identifying and quantifying abnormal retinal fluids, as well as anatomic changes within the retina.
Read More
For the first time, the U.S. Food and Drug Administration (FDA) has approved a drug for the treatment of geographic atrophy (GA), one of the advanced forms of dry age-related macular degeneration (AMD).
Read More
This case study of a patient with Leber hereditary optic neuropathy (LHON) showcases the diagnostic value of the SPECTRALIS.
Read More
ANTERION® from Heidelberg Engineering is a comprehensive all-in-one-solution for optical biometry and IOL power predictions. ANTERION provides high-resolution images of the anterior segment by combining SS-OCT technology with eye tracking.
Read More
Chris Lievens, OD, “The 4 Eyed Professor” recently sat down with Heidelberg Engineering employees Cindy Armstrong, Clinical Application Specialist and Joey Hatfield, Director of Sales South, to unpack some myths about SPECTRALIS and explore its applications in optometry to enhance patient care.
Read More
Dr. Robert Sergott highlights the value of SPECTRALIS multicolor OCT imaging in the diagnosis and management of patients with systemic disease.
Read More
Join us in Berlin, May 26 - 27, 2023, to celebrate the 20th anniversary of our esteemed International SPECTRALIS Symposium (ISS)!
Read More
This journal article highlights the value of SPECTRALIS OCT volume scans in identifying biomarkers of age-related macular degeneration.
Read More
Sophia Pathai, MD, PhD, host of the Ophthalmic Innovation Source podcast, caught up with our Head of Corporate Strategy and Managing Director of MSI, Kfir Azoulay, as well as Tosh Vadhia, Managing Director of Heidelberg Engineering UK, to talk about the trends and opportunities in ophthalmology, including OCT-based biomarkers and artificial intelligence.
Read More
